Screening of Extended-Spectrum β-Lactamases (ESBL)-producing Klebsiella pneumoniae with ChromID ESBL Media

Emy Noerwidayati, Andaru Dahesihdewi, Osman Sianipar

Abstract


BACKGROUND: Klepsiella pneumoniae, one of clinical isolates, is frequently found causative agent of hospital acquired infection. Currently, K. pneumoniae is found as extended-Spectrum β-lactamases (ESBL) producer, allowing it to become multidrugresistant. A clinical laboratory with limited facility needs a valid, reliable, inexpensive and simple laboratory test to control its infection and antimicrobial-resistancy. The aim of this study is to evaluate the diagnostic performance of a ESBL media to detect ESBL-producing K. pneumoniae.

METHODS: An independent and blind comparative study of ChromID ESBL media and Double Disc Synergy Test (DDST) was conducted for detecting the clinical isolate of ESBL-producing K. pneumoniae. Clinical isolates of K. pneumoniae collected from the Clinical Laboratory of Dr. Sardjito Hospital were isolated.

RESULTS: There were 103 clinical isolates of K. pneumoniae, which were isolated from urine, pus, blood, stool, cerebrospinal fluid, sputum, drain liquid, nasal sinus liquid, gastric wash, bronchi liquid, injury liquid and nasal swab. The number of true positive, true negative, false positive and false negative results were 74, 18, 9 and 2, respectively. Meanwhile, the sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio for positive result and likelihood ratio for negative result of the new ESBL media were 97.4%, 66.7%, 89.2%, 90%, 2.9 and 0.03, respectively.

CONCLUSION: Since the new ESBL media and DDST results were similar, so the new ESBL media could be used for screening patients with clinical presentation that indicating a high suspicious of ESBL-producing bacteria.

KEYWORDS: K. pneumoniae, ChromID ESBL, DDST, ESBL, sensitivity


Full Text:

PDF

References


Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance :science for intervention. New Microbes New Infect 2015; 6: 22-9, CrossRef.

Lee C, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of Klebsiella pneumoniae : epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016; 7: 895, CrossRef.

Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: definition, classification and epidemiology. Curr Issues Mol Biol. 2015; 17: 11-22, CrossRef.

Subashini J, Kannabiran K. Screening and identification of extended spectrum β-lactamase (ESBL) pathogens in urine sample of UTI Patient’s. Trop Med Surg. 2013; 1: 120, CrossRef.

Numanovic F, Hukic M, Delibegovic Z, Tihic N, Pasic S, Gegic M. Comparison of double disk synergy test, VITEK 2 and Check-MDR CT102 for detection of ESBL producing isolates. Acta Med Acad. 2013; 42: 15-24, CrossRef.

Diederen BMW, Leest M Van, Van I, Willemse P, Keulen PHJ Van, Jan AJW, et al. Performance of MRSA ID, a new chromogenic medium for detection of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2006 Feb; 44(2): 586-8, CrossRef.

Pfaller MA, Segreti J. Overview of the epidemiological profileand laboratory detection of extended-spectrum β-Lactamases. Clin Infect Dis. 2006; 42: S153-63, CrossRef.

Réglier-Poupet H, Naas T, Carrer A, Cady A, Adam JM, Fortineau N, et al. Performance of chromID ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum β-lactamases. J Med Microbiol. 2008; 57: 310-5, CrossRef.

Clinical Laboratory Standards Institute. M100S Performance Standards for Antimicrobial. Wayne: Clinical and Laboratory Standards Institute; 2016, article.

Wiegand I, Geiss HK, Mack D, Stürenburg E, Seifert H. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol. 2007; 45: 1167-74, CrossRef.

Harada S, Ishii Y, Yamaguchi K. Extended-spectrum β-Lactamases: implications for the clinical laboratory and therapy. Korean J Lab Med. 2008; 28: 401-12, CrossRef.

Yang CC, Wu CH, Lee CT, Liu HT, Chen JB, Chiu CH, et al. Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy. Int J Infect Dis. 2014; 28: 3-7, CrossRef.

Liu YM, Li BB, Zhang YY, Zhang W, Shen H, Li H, et al. Clinical and molecular characteristics of emerging hypervirulent Klebsiella pneumoniae bloodstream infections in mainland China. Antimicrob Agents Chemother 2014; 58: 5379-85, CrossRef.

Gupta A, Ampofo K, Rubenstein D, Saiman L. Extended spectrum β lactamase-producing Klebsiella pneumoniae infections: A review of the literature. J Perinatol. 2003; 23: 439-43, CrossRef.

Färber J, Moder KA, Layer F, Tammer I, König W, König B. Extended-spectrum beta-lactamase detection with different panels for automated susceptibility testing and with a chromogenic medium. J Clin Microbiol. 2008; 46: 3721-7, CrossRef.

Huang T, Bogaerts P, Berhin C, Guisset A, Glupczynski Y. Evaluation of brilliance ESBL agar, a novel chromogenic medium for detection of extended-spectrum-beta-lactamase-producing enterobacteriaceae. 2010; 48: 2091-6, CrossRef.




DOI: https://doi.org/10.18585/inabj.v10i3.430

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute